07.09.2017 - CheckMate-214 Study Evaluating Nivolumab in Combination with Ipilimumab Stopped Early for Demonstrating Overall Survival Benefit

07.09.2017 - Pressemitteilung der Bristol-Myers Squibb GmbH & Co. KGaA 
Nivolumab plus Ipilimumab showed superior overall survival versus current standard of care sunitinib in intermediate- and poor-risk patients, a co-primary endpoint. The combination also met the secondary endpoint of improved overall survival in all randomized patients

Zuletzt aufgerufen am: 20.01.2021 09:41